Foghorn Therapeutics Inc. (FHTX) vs Insight Molecular Diagnostics Inc. (IMDX)
A side-by-side comparison of Foghorn Therapeutics Inc. and Insight Molecular Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FHTX
Foghorn Therapeutics Inc.
$1.91HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
IMDX
Insight Molecular Diagnostics Inc.
$3.73HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — FHTX vs IMDX
growth of $100 · dividends reinvested · last 6yFHTX -89.0% (-30.7%/yr)IMDX -89.1% (-30.9%/yr)FHTX compounded faster over this window
FHTX IMDX
FHTX vs IMDX: by the numbers
- •IMDX is the larger company ($120M vs $112M market cap).
- •Both run net losses; FHTX's is the smaller (-175.78% vs -2955.63% net margin).
- •FHTX grew revenue faster over the past five years (105.83% vs 27.24% CAGR).
Metrics side by side
Valuation
| Metric | FHTX | IMDX |
|---|---|---|
| P/S ratio | 3.05 | 72.02 |
Profitability
| Metric | FHTX | IMDX |
|---|---|---|
| Gross margin | 89.22% | 11.17% |
| Operating margin | -265.64% | -754.08% |
| Net margin | -175.78% | -2955.63% |
| ROIC | -44.81% | -223.06% |
Growth (annualized)
| Metric | FHTX | IMDX |
|---|---|---|
| Revenue CAGR (5Y) | 105.83% | 27.24% |
| Total return CAGR (5Y) | -31.87% | -44.39% |
Frequently asked
- Which has grown faster, FHTX or IMDX?
- Over the past five years, FHTX grew revenue faster — FHTX at a 105.83% CAGR versus IMDX at 27.24%.
- How have FHTX and IMDX total returns compared?
- Over the past 5 years, FHTX delivered -31.87% and IMDX delivered -44.39% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Foghorn Therapeutics ROEInsight Molecular Diagnostics ROEFoghorn Therapeutics operating marginInsight Molecular Diagnostics operating marginFoghorn Therapeutics revenue growthInsight Molecular Diagnostics revenue growthFoghorn Therapeutics free cash flowInsight Molecular Diagnostics free cash flow
Foghorn Therapeutics & Insight Molecular Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.